<table border="1" id="t3124432828" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3:  Clinically Significant Drug Interactions with HYSINGLA
ER</caption>
<colgroup>
<col width="24*"></col>
<col width="75*"></col>
</colgroup>
<tbody>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Inhibitors
of CYP3A4</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of HYSINGLA
ER and CYP3A4 inhibitors can increase the plasma concentration of
hydrocodone, resulting in increased or prolonged opioid effects. These
effects could be more pronounced with concomitant use of HYSINGLA
ER and CYP3A4 inhibitors, particularly when an inhibitor is added
after a stable dose of HYSINGLA ER is achieved <content stylecode="italics">[see Warnings
and Precautions (<linkhtml href="#Section_5.4">5.4</linkhtml>)]</content>.<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor
decline, the hydrocodone plasma concentration will decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, resulting in decreased opioid efficacy or a withdrawal
syndrome in patients who had developed physical dependence to hydrocodone.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">If concomitant use is necessary,
consider dosage reduction of HYSINGLA ER until stable drug effects
are achieved. Monitor patients for respiratory depression and sedation
at frequent intervals.<br/>If a CYP3A4 inhibitor is discontinued,
consider increasing the HYSINGLA ER dosage until stable drug effects
are achieved.  Monitor for signs of opioid withdrawal.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Macrolide antibiotics (e.g.,
erythromycin), azole-antifungal agents (e.g. ketoconazole), protease
inhibitors (e.g., ritonavir)</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of HYSINGLA
ER and CYP3A4 inducers can decrease the plasma concentration of hydrocodone <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, resulting in decreased efficacy or onset of a withdrawal
syndrome in patients who have developed physical dependence to hydrocodone <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#Section_5.4">5.4</linkhtml>)]</content>.<br/>After stopping a CYP3A4 inducer, as the effects
of the inducer decline, the hydrocodone plasma concentration will
increase <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, which could increase or prolong both the
therapeutic effects and adverse reactions, and may cause serious respiratory
depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">If concomitant use is necessary,
consider increasing the HYSINGLA ER dosage until stable drug effects
are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4
inducer is discontinued, consider HYSINGLA ER dosage reduction and
monitor for signs of respiratory depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Rifampin, carbamazepine, phenytoin</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Benzodiazepines
and Other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Due to additive pharmacologic
effect, the concomitant use of benzodiazepines or other CNS depressants,
including alcohol, can increase the risk of hypotension, respiratory
depression, profound sedation, coma, and death.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Reserve concomitant prescribing
of these drugs for use in patients for whom alternative treatment
options are inadequate. Limit dosages and durations to the minimum
required. Follow patients closely for signs of respiratory depression
and sedation <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#Section_5.5">5.5</linkhtml>)]</content>.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Benzodiazepines and other sedatives/hypnotics,
anxiolytics, tranquilizers, muscle relaxants, general anesthetics,
antipsychotics, other opioids, alcohol.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Serotonergic
Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of opioids
with other drugs that affect the serotonergic neurotransmitter system
has resulted in serotonin syndrome.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">If concomitant use is warranted,
carefully observe the patient, particularly during treatment initiation
and dose adjustment.  Discontinue HYSINGLA ER if serotonin syndrome
is suspected.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Selective serotonin reuptake
inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors
(SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor
antagonists, drugs that affect the serotonin neurotransmitter system
(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO)
inhibitors (those intended to treat psychiatric disorders and also
others, such as linezolid and intravenous methylene blue).</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Monoamine
Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">MAOI interactions with opioids
may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory
depression, coma)<content stylecode="italics"> [see Warnings and Precautions (<linkhtml href="#Section_5.2">5.2</linkhtml>)]</content>.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The use of HYSINGLA ER is not
recommended for patients taking MAOIs or within 14 days of stopping
such treatment.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Phenelzine, tranylcypromine,
linezolid</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Mixed Agonist/Antagonist
and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">May reduce the analgesic effect
of HYSINGLA ER and/or precipitate withdrawal symptoms.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Avoid concomitant use.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">butorphanol, nalbuphine, pentazocine,
buprenorphine</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Hydrocodone may enhance the
neuromuscular blocking action of skeletal muscle relaxants and produce
an increased degree of respiratory depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
respiratory depression that may be greater than otherwise expected
and decrease the dosage of HYSINGLA ER and/or the muscle relaxant
as necessary.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Opioids can reduce the efficacy
of diuretics by inducing the release of antidiuretic hormone.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
diminished diuresis and/or effects on blood pressure and increase
the dosage of the diuretic as needed.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Anticholinergic
Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">The concomitant use of anticholinergic
drugs may increase risk of urinary retention and/or severe constipation,
which may lead to paralytic ileus.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
urinary retention or reduced gastric motility when HYSINGLA ER is
used concomitantly with anticholinergic drugs.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Strong Laxatives</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Concomitant use of HYSINGLA
ER with strong laxatives that rapidly increase gastrointestinal motility,
may decrease hydrocodone absorption and result in decreased hydrocodone
plasma levels.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">If HYSINGLA ER is used in these
patients, closely monitor for the development of adverse events as
well as changing analgesic requirements.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Example:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule">Lactulose</td>
</tr>
</tbody>
</table>